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Abstract ChgA has recently been identified as the autoantigen for diabetogenic CD4+ T cells in
NOD mice and T1D patients. However, autoreactive CD8+ T-cell responses targeting ChgA haven't
been studied yet. Here several HLA-A*0201-restricted peptides derived from mChgA and hChgA
were selected by an integrated computational prediction approach, followed by an HLA-A*0201
binding assay. MChgA10–19 and mChgA43–52 peptides, which bound well with HLA-A*0201 molecule,
induced significant proliferation and IFN-γ-releasing of splenocytes from diabetic NOD.β2mnull.HHD
mice. Notably, flow cytometry analysis found that mChgA10–19 and mChgA43–52 stimulated the
production of IFN-γ, perforin, and IL-17 by splenic CD8+ T cells of diabetic NOD.β2mnull.HHD mice.
Furthermore, hChgA10–19 and hChgA43–52-induced IFN-γ releasing by specific CD8
+ T cells were
frequently detected in recent-onset HLA-A*0201-positive T1D patients. Thus, this study demonstrated
that autoreactive CD8+ T cells targeting ChgA were present in NOD.β2mnull.HHD mice and T1D
patients, and might contribute to pathogenesis of T1D through secreting proinflammatory cytokines
and cytotoxic molecules.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).@126.com (M. Zhang), liwang1
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64 Y. Li et al.1. Introduction
Type 1 diabetes (T1D) is an autoimmune disease character-
ized by T cell-mediated destruction of insulin-producing
pancreatic islet β cells [1]. It has been commonly accepted
that CD4+ T cells play an important role in initiation and
progression of T1D [2]. However, autoreactive CD8+ T cells
have been proved to play an indispensable key role in the
destruction of islet β cells and development of T1D [3]. CD8+
T cells may be the early initiators that mediated the
destruction of islet β cell in nonobese diabetic (NOD) mice.
MHC class I molecule-deficient NOD mice do not develop
insulitis [4,5], and some islet-derived CD8+ T cell clones
transfer diabetes in the absence of CD4+ T cells [6,7].
Several observations in humans also inferred the functional
importance of CD8+ T cells in the destruction of human islet
β cells [8–11]. Thus, the identification of epitopes from islet
β cell antigen recognized by CD8+ T cells in humans not only
can provide new tools for a more accurate prediction of T1D,
but also is important for the elaboration of new immuno-
therapeutic strategies.
Interestingly, most β-cell antigens, such as insulin [12,13],
glutamic acid decarboxylase (GAD) [14,15], and islet-specific
glucose-6-phosphatase catalytic subunit-related protein (IGRP)
[16,17], can be recognized by both islet-specific CD4+ T cells
and CD8+ T cells. Chromogranin A (ChgA) has recently been
identified as an autoantigen for diabetogenic CD4+ T cells in
both NODmice [18,19] and human T1D subjects [20]. However,
it remains unknown whether ChgA can be recognized by
autoreactive CD8+ T cells in T1D. Human histocompatibility
leukocyte antigen-A*0201 (HLA-A*0201) is the most commonly
expressed HLA class I allele in Caucasians and Asians (50%), and
contributes to the susceptibility to T1D [21]. T1D onset is
significantly accelerated in HLA-A*0201 transgenic NOD mice
with HLA-A*0201-restricted CD8 T cells appearing in early,
prediabetic insulitic lesions [22]. Therefore, several studies
have used humanized NOD.β2mnull.HHD mice to identify β
cell autoantigen-derived peptides that are recognized by
HLA-A*0201-restricted CD8+ T cells with potential clinical
relevance to human T1D [21,23,24]. However limited peptides
have been identified as targets recognized by HLA-A2-
restricted CD8+ T cells in human T1D. In this study, we tested
the autoreactivities of CD8+ T cells against several HLA-
A*0201-restricted candidate epitopes from murine and human
ChgA protein in NOD.β2mnull.HHD mice and HLA-A*0201
positive T1D patients, respectively.
2. Materials and methods
2.1. Mice and T1D subjects
NOD.β2mnull.HHD mice were purchased from the Jackson
Laboratory (Bar Harbor, Maine, USA). The mice were bred
and maintained in specific pathogen-free facilities. All
animals were treated according to “Principles of Laboratory
Animal Care and Use in Research” (Ministry of Health,
Beijing, China). All experimental protocols were approved
by the Animal Ethics Committee of the Third Military Medical
University.
Fresh blood samples were obtained from 10 HLA-A*0201-
positive (age [mean ± SD] 10.3 ± 3.4 years, range 5–14 years,40% female) and 5 HLA-A*0201-negative (10.4 ± 5.0, 5–18, 40%)
T1D patients and 8 HLA-A*0201-positive healthy controls
(29.6 ± 7.2, 22–41, 50%). All patients with recent-onset T1D
(disease duration 5–389 days) were lean and presented at
diagnosis with acute onset of symptoms, and have required
permanent insulin treatment from the time of diagnosis. These
patients were all positive for autoantibodies to islet cell, GAD
and/or insulin. HLA-A*0201-positive T1D patients and healthy
controls were identified by flow cytometry (BD Bioscience,
Franklin Lakes, NJ, USA) using an aliquot of the cells stained
with allophycocyanin (APC)-conjugated anti-HLA-A2 mAb BB7.2
(eBiosciences, San Diego, CA, USA). The study protocol was
approved by the ethics committee of the Third Military Medical
University, and informed consent was obtained from all
participating subjects in this study.
2.2. Peptides
To screen candidate HLA-A*0201 binding peptides within murine
Chromogranin A (mChgA) (GeneBank accession no. P26339) and
human ChgA (hChgA) (GeneBank accession no. P10645), an
integrated approach combining three online T-cell epitope
prediction algorithms including SYFPEITHI (http://www.
syfpeithi.de/), IEDB (http://tools.immuneepitope.org/mhci/),
and NetMHC (http://www.cbs.dtu.dk/services/NetMHC/) was
used. The peptides scored top 10 were collected in SYFPEITHI
method, and the cutoff standard of other two methods is
IC50 b 500 nm. The predicted candidate m/hChgA pep-
tides and control peptides (HIV Pol476–484 ILKEPVHGV,
IGRP206–214 VYLKTNVFL, mInsA2–10 IVDQCCTSI, IGRP265–273
VLFGLGFAI), were synthesized with purity N95% at Chinese
Peptide Company (Hangzhou, China). These peptides were
dissolved in DMSO (dimethyl sulfoxide, DMSO) at a concentra-
tion of 20 mg/mL, and stored at −80 °C.
2.3. HLA-A*0201 binding assay
T2 cells (1 × 106/mL) were incubated with each peptide
(10 μg/mL) and 3 μg/mL beta-2-microglobulin (Sigma-Aldrich,
St. Louis, MO, USA) for 16 h at 37 °C. Then the cells were
washed and stained with anti-HLA-A2 mAb BB7.2 (BD Biosci-
ence), followed by incubation with FITC-conjugated goat anti-
mouse IgG (Beyotime, Jiangsu, China), and analyzed using an
FACS Canto cytometer (BD Bioscience).
2.4. Splenocyte proliferation assay
Splenocytes freshly isolated from 12- to 16-week-old
diabetic female NOD.β2mnull.HHD mice were co-cultured in
triplicate with 10 μg/mL indicated peptides in 96-well
plates. After incubation at 37 °C for 72 h, [3H] thymidine
(1 μCi/well) was added for an additional 16 h of culture, and
uptake of [3H] thymidine was determined using a liquid
scintillation counter (Beckman Coulter, Brea, CA, USA).
2.5. Mouse or human IFN-γ ELISPOT assays
ELISPOT plates were precoated with anti-mouse or anti-
human IFN-γmAb (MabTech, Stockholm, Sweden) overnight
at 4 °C, and blocked with RPMI 1640 plus 10% FBS (HyClone
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(5 × 105 cells/well) from 12- to 16-week-old diabetic female
NOD.β2mnull.HHD mice were incubated with each peptide
(50 μg/mL)-pulsed T2 cells (5 × 104 cells/well) for 36 h at
37 °C. For human IFN-γ assays, CD8+ T cells in PBMC were
purified from T1D patients or healthy controls by using the
EasySep CD8+ T cell enrichment kit (StemCell Technolo-
gies, Vancouver, Canada). Purified human CD8+ T cells
(purity N90%, 1 × 105 cells/well) were incubated with
each peptide (50 μg/mL)-pulsed T2 cells (1 × 104 cells/
well) for 24 h at 37 °C. After incubation, the cells were
removed and plates were processed according to the IFN-γ
ELISPOT kit (MabTech) manufacturer's instructions. Spots
were counted using a spot reader system (Saizhi, Beijing,
China).Figure 1 HLA-A*0201 binding assay of m/hChgA-derived
peptides. T2 cells were incubated with each peptide and the
stabilization of surface HLA-A2 molecules was detected by flow
cytometry. Each bar represents fluorescence index (FI). FI was
calculated as follows: FI = (mean fluorescence intensity with the
given peptide − mean fluorescence intensity without peptide) /
(mean fluorescence intensity without peptide).2.6. Flow cytometry
Mouse splenic CD8+ T cells were purified by negative selection
from 12- to 16-week-old diabetic female NOD.β2mnull.HHD
mice by using magnetic separation (Miltenyi Biotec, Bergisch
Gladbach, Germany). Purifiedmouse CD8+ T cells (purity N 85%,
1 × 105 cells/200 μL/well) were stimulated with each peptide
(50 μg/mL)-pulsed T2 cells (5 × 104 cells/well). One hour later,
0.65 μL/mL GolgiStop™ (BD Bioscience) was added into each
culture for additional 5 h-incubation at 37 °C. For intracellular
cytokine staining, the cells were firstly surface-stained with
PerCP5.5-conjugated anti-mouse CD8 (Sungene, Tianjing,
China), and then fixed and stained for APC-conjugated
antibodies against IFN-γ and PE-conjugated antibodies
against perforin, or PE-conjugated antibodies against
mouse IL-17A (eBiosciences) using the Fixation/Perme-
abilization kit (eBiosciences) according to the
manufacturer's instructions. To determine whether the
peptide-induced cytokine production is HLA-I-dependent,
purified anti-human HLA-ABC antibody (eBioscience)
was used at a final concentration of 10 μg/mL.
Isotype-matched controls were included in all experi-
ments. Events were collected on the BD Acurri C6 flow
cytometer and analyzed with FlowJo software.2.7. Statistics
Results are expressed as mean ± SD. The unpaired t-test
was used to make comparisons between different treatmentTable 1 Predicted mChgA and hChgA epitopes binding to HLA-A*
Source Position Sequence Net
mChgA 8–16 ALLLCAGQV 287
hChgA 8–16 ALLLCAGQV 287
mChgA 10–19 LLCAGQVFAL 37
hChgA 10–19 LLCAGQVTAL 169
mChgA 43–52 SLSKPSPMPV 30
hChgA 43–52 TLSKPSPMPV 56
mChgA 75–84 LLKELQDLAL 613
hChgA 75–84 LLKELQDLAL 613
Underlined letters indicated amino acid differences between murine andgroups. P values of b0.05 were considered statistically
significant.3. Results
3.1. Selection of potential HLA-A*0201-restricted
epitopes in mChgA and hChgA
To identify the mChgA and hChgA epitopes recognized
by CD8+ T cells, we predicted HLA-A*0201-binding candi-
dates through integrating three online algorithms. Pep-
tides m/hChgA 8–16, m/hChgA 10–19, m/hChgA 43–52 were
predicted as good HLA-A*0201 binders by all algorithms,
whereas peptide m/hChgA75–84 was predicted positively
only by SYFTEPITHI (Table 1). These four pairs of m/h ChgA
peptides were selected to synthesize because their
sequences are identical to or differ from each other only
in one single residue (Table 1).0201 molecules.
MHC score SYFTEPITHI score IEDB score
24 122.21
24 122.21
27 82.70
27 220.54
22 76.29
20 104.83
25 967.12
25 967.12
human ChgA peptide sequences.
Figure 2 Splenocyte proliferative responses to mChgA pep-
tides. Splenocytes were isolated from seven 12- to 16-week-old
diabetic female NOD.β2mnull.HHD mice, and then cells per mice
were treated with 10 μg/mL indicated peptides or no peptide
for 72 h in 96-well plates (2 × 105 per well) at 37 °C. The cell
proliferation was measured by [3H] thymidine incorporation.
Data are presented as mean of triplicate cultures per mice. SD
are not shown to avoid excessive visual clutter.
Figure 3 IFN-γ ELISPOT assays of splenocyte responses to mChgA
splenocyte responses to T2 cell loaded with each indicated peptides o
B: The average number of peptide-specific IFN-γ-positive spots per 5
indicated peptides or no peptide from twelve separated experiment
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A*0201 molecule
To confirm this prediction, the binding affinity of these
peptides for HLA-A*0201 molecule was determined by a T2
cell-based binding assay. An HLA-A*0201-restricted epitope
HIV Pol476–484 and an H2-Kd restricted epitope IGRP206–214
were used as positive and negative controls, respectively. As
indicated in Fig. 1 and Supplementary Fig. 1, m/hChgA10–19
and m/hChgA43–52 which were predicted as strong HLA-A*0201
binders, showed high actual binding affinity for HLA-A*0201;
bothm/hChgA8–16 predicted as a moderate HLA-A*0201 binder
and m/hChgA75–84 predicted as a poor HLA-A*0201 binder
displayed undetectable HLA-A*0201-binding capacity.3.3. Proliferative and IFN-γ responses of
splenocytes from NOD.β2mnull.HHD mice
to mChgA candidate peptides
To assess activation of T cells derived by various peptides, we
measured proliferation of splenocytes from 12- to 16-week-old
diabetic female NOD.β2mnull.HHD mice upon the stimulation
with indicated peptides. Splenocyte proliferation induced bypeptides. A: Representative IFN-γ ELISPOT assay demonstrated
r no peptide in 12- to 16-week-old diabetic female NOD.β2mnull.
× 105 splenocytes in triplicate cultures was calculated for each
s. SD are not shown to avoid excessive visual clutter.
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weaker than that induced by the known immunodomi-
nant HLA-A*0201-restricted mouse insulin A chain peptide
(mInsA2–10) epitope. Whereas no positive splenocyte prolifera-
tion induced by either mChgA8–16, mChgA75–84 or medium
control was observed (Fig. 2).
Furthermore, we performed IFN-γ ELISPOT analysis using
each peptide pulsed-T2 cells as target cells. As shown in
Figs. 3A and B, compared with peptide-free-T2 cells, the
peptide mInsA2–10-pulsed T2 cells stimulated abundant IFN-γ
spots forming, and T2 cells loaded with mChgA10–19 and
mChgA43–52 could also stimulate obvious IFN-γ secretion by
splenocytes from diabetic NOD.β2mnull.HHD mice. No signif-
icant specific IFN-γ-producing cell reactivity was detected in
splenocytes stimulated with T2 pulsed with mChgA8–16 or
mChgA75–84. These results together indicated that HLA-A*0201
well presented peptides mChgA10–19 and mChgA43–52 could
effectively stimulate the proliferation and IFN-γ releasing of
splenocytes from diabetic NOD.β2mnull.HHD mice.Figure 4 Intracellular cytokine staining of peptide-specific CD8+
purified CD8+ T cells stimulated by T2 cells pulsed with mChgA10–19, m
alone (no peptide) was used as blank control. Anti-HLA-ABC (10 μg/m
the HLA class I restriction of CD8+ T-cell responses to each peptide. T
(B) of three independent experiments are shown.3.4. HLA-A*0201-restricted CD8+ T-cell responses
to mChgA10–19 and mChgA43–52 in NOD.β2mnull.HHD
mice
To establish whether the mChgA peptides could induce HLA-
A*0201-restricted CD8+ T-cell responses in NOD.β2mnull.HHD
mice, splenic CD8+ T cells were purified and their capacity to
produce IFN-γ, perforin, and IL-17 were analyzed by flow
cytometry. As shown in Figs. 4A and B, T2 cells pulsed with
mChgA10–19, mChgA43–52 as well as mInsA2–10 stimulated the
production of IFN-γ, perforin, and IL-17 by splenic CD8+ T cells
of diabetic NOD.β2mnull.HHDmice. The IFN-γ-producing CD8+ T
cells simultaneously secreted perforin, but no IL-17, whereas
the IL-17-producing CD8+ T cells expressed high amounts of
IL-17, but no IFN-γ (data not shown). Moreover, the production
of these effectors molecules by CD8+ T cells was almost
completely blocked by adding the anti-HLA-ABC antibody
(Fig. 4A). These results demonstrated that mChgA10–19 and
mChgA43–52 peptides are novel targets of HLA-A*0201-T cells ex vivo. The expression of IFN-γ, perforin and IL-17A by
ChgA43–52 or mInsA2–10 was detected by flow cytometry. The T2
L) (+) or isotypic control (10 μg/mL) (−) was added for analyzing
he representative FACS density plots (A) and statistical analysis
Table 2 IFN-γ ELISPOT analysis of human CD8+ T cell responses to hChgA peptides.
% positive HLA-A*0201+ T1D patients (n = 10)
P01 P02 P03 P04 P05 P06 P07 P08 P09 P10
hChgA10–19 20 (2/10) 54 58 72 85 160 47 65 106 102 105
hChgA43–52 30 (3/10) 51 63 88 81 171 59 66 83 127 98
IGRP265–273 40 (4/10) 77 150 67 112 177 53 93 91 105 102
Positive control 100 (10/10) 349 524 408 636 681 312 279 445 530 550
Basal + 3SD 62 133 77 93 151 70 79 99 115 135
Basal 47 80 50 76 117 52 63 85 91 107
HLA-A*0201− T1D patients (n = 5) HLA-A*0201+ healthy controls (n = 8)
% positive P11 P12 P13 P14 P15 C1 C2 C3 C4 C5 C6 C7 C8
hChgA10–19 0 (0/13) 156 33 79 80 61 141 56 99 111 59 82 127 96
hChgA43–52 0 (0/13) 123 28 75 89 56 135 52 93 117 57 75 135 89
IGRP265–273 0 (0/13) 151 50 83 95 64 156 99 101 106 66 86 143 87
Positive control 100 (13/13) 612 357 572 553 448 841 535 468 589 368 412 639 558
Basal + 3SD 191 55 98 110 80 170 112 118 137 78 101 161 109
Basal 159 32 81 92 62 128 65 97 113 63 77 132 94
Positive control: a mix of 20 ng/mL Phorbol-12-myristate-13-acetate (PMA) and 400 ng/mL ionophore (Ion). Readouts are expressed as spot-forming
cells/105 CD8+ T cells. Data are presented as mean of triplicate cultures. The positive cut-off was set at 3SD above the average background responses
against T2 pulsed with no peptide. Positive reactivities corresponding to values above basal + 3SD are underlined.
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tory and cytolytic capacity in diabetic NOD.β2mnull.HHD
mice.
3.5. CD8+ T-cell reactivities to hChgA10–19
and hChgA43–52 in T1D patients
We then performed human IFN-γ ELISPOT directly to investi-
gate whether CD8+ T-cell responses to hChgA10–19 and
hChgA43–52 exist in T1D patients. As shown in Table 2 and
Fig. 5, hChgA10–19 and hChgA43–52 were recognized by CD8+ T
cells in about 20% and 30% of HLA-A*0201+ T1D patients,
respectively. The CD8+ T cell response to a known immuno-
dominant HLA-A*0201-restricted epitope IGRP265–273 was
detected in almost 40% of HLA-A*0201+ T1D patients. And
the two tested hChgA epitopes weren't recognized by CD8+ T
cells from either HLA-A*0201+ healthy controls or HLA-A*0201−
T1D patients. These results indicated that hChgA10–19 and
hChgA43–52 were novel targets of HLA-A*0201-restricted
autoreactive CD8+ T cells in T1D patients.
4. Discussion
Although the major role of autoreactive CD8+ T cells in T1D
has been well established, knowledge of the target
autoantigens for CD8+ T cells especially in human T1D
patients is relatively limited. ChgA, present in secretory
granules of islet β cells and other neuroendocrine tissues, is
identified to be a new autoantigen for autoreactive CD4+ T
cells in NOD mice and human T1D [18,20]. However,
autoreactive CD8+ T-cell responses targeting ChgA have
not been studied yet. Herein, we firstly reported that
autoreactive CD8+ T cells targeting ChgA existed in both
NOD.β2mnull.HHD mice and T1D patients. Peptides ChgA10–19and ChgA43–52 were identified as novel HLA-A*0201-restrict-
ed epitopes relevant to T1D. So far, several β-cell antigens,
such as insulin [25], GAD65 [26], zinc transporter 8 [27], as
well as ChgA, have been found to be targeted by both
diabetogenic CD8+ and CD4+ T cells in NOD mice and T1D
patients, suggesting that the recognition of the same
autoantigen by autoreactive CD4+ and CD8+ T cells may
benefit the formation of a proximal relationship between
them and greatly contribute to the pathogenesis of autoim-
mune diseases.
It is indicated that the peptide WE14, a natural proteolytic
cleavage product from ChgA, can be converted into a highly
antigenic epitope for BDC-2.5 CD4+ T cell clone through the
enzyme transglutaminase-dependent modification [28].
Recent study shows that WE14 is also recognized by T cells
from diabetic patients and treatment with transglutamin-
ase increased reactivity to WE14 peptide in some patients
[20]. The two HLA-A*0201-restricted ChgA epitopes identified
here are not included in WE14, but ChgA43–52 is adjacent to
ChgA 29–42 peptide, which is shown to be able to induce
cellular and humoral immune responses in NOD mice [29].
HLA-A*0201 is one important HLA class I allele relevant to
T1D [21]. Some autoantigenic peptides that were identified
to be recognized by CD8+ T cells in NOD mice expressing
HLA-A*0201 molecules have been shown to be targets for
HLA-A*0201-restricted CD8+ T cells in T1D patients [30,31].
Through an integrated computational prediction approach,
we selected four HLA-A*0201-binding candidate peptide
pairs derived from murine and human ChgA protein. A
positive correlation between the predicted binding affinity
and the magnitude of HLA-A*0201 stabilization was ob-
served, and two peptides mChgA10–19 and mChgA43–52 with
an actual positive binding affinity for HLA-A*0201 could
obviously stimulate the proliferation of splenocytes from
HLA-A*0201-transgenic NOD mice, again suggesting the high
Figure 5 A representative image of an IFN-γ ELISPOT assay for CD8+ T cells from HLA-A*0201+ T1D patients, HLA-A*0201− T1D
patients, and HLA-A*0201+ healthy controls. Spot number counts are expressed as spot-forming cells/105 CD8+ T cells for each well.
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cell epitopes [32].
IFN-γ, which is mainly produced by autoreactive T cells,
is generally believed to be a key pathogenic factor in T1D.
IFN-γ ELISPOT assay has been always used for detection and
enumeration of autoreactive T cells in T1D mouse models and
patients. We showed that peptides mChgA10–19 and mChgA43–52
could induce specific T cell response in NOD.β2mnull.HHD mice
as determined by IFN-γ ELISPOT assay. However, this assay
cannot identify individual cytokine-producing cells. By combin-
ing surface staining and intracellular cytokine staining, we
further demonstrated that mChgA peptide-induced cytokine
production was absolutely medicated by CD8+ T cells and this
process was completely blocked by a antibody against HLA class
I molecules, again confirming the HLA-A*0201 restriction. Very
interestingly, we observed that some of mChgA peptide-
reactive CD8+ T cell clones displayed a marked cytotoxic
activity by producing IFN-γ and perforin, and some other CD8+
T cell clones released high amounts of IL-17 but little IFN-γ, just
similar to mInsA2–10-induced CD8+ T cell response profile.
Although the autoreactive cytotoxic CD8+ T cells have been
shown to directly mediate the destruction of islet β cells,
several recent findings highlight the role of proinflammatoryIL-17 immunity in the pathogenesis of autoimmune diabetes
mice model [33] and human T1D [34]. An increase in both CD4+
and CD8+ T cells that secreted IL-17 has been reported in the
peripheral blood of children with recent onset T1D [35].
Blocking the generation of Th17 cells with the administration
of B7-H4.Ig effectively prevented T1D development in NOD
mice [36]. A recent study demonstrated that the autoantigen-
specific IL-17-producing CD8+ T cells (Tc17) could be home to
the pancreatic lymph nodes without causing any pancreatic
infiltration or tissue destruction when transferred alone, but
could potentiate the Th1-mediated disease progression [37].
Our results indicated β-cell autoantigens such as insulin and
ChgA could generate HLA-A*0201-restricted autoreactive CD8+
T cells with the proinflammatory and cytolytic capacity, which
might both participate in the pathogenesis of T1D.
It has been commonly accepted that the interaction
between epitope peptide and HLA-A*0201 molecule mainly
depends on anchor residues at position 2 and 9 [38]. Our
results indicated that the mouse ChgA-derived peptides
mChgA10–19/mChgA43–52 and their human counterparts,
which differ from each other by only a single residue at position
8 or 1, have similar binding affinity with HLA-A*0201, intensively
implying that hChgA10–19 and hChgA43–52 peptides would be
70 Y. Li et al.recognized by CD8+ T cells in HLA-A*0201+ T1D patients.
Expectedly, we demonstrated that the two peptides
hChgA10–19 and hChgA43–52 induced IFN-γ response in a
fraction of HLA-A*0201+ T1D patients, but neither in
HLA-A*0201+ healthy controls nor in HLA-A*0201− T1D
patients. Our human IFN-γ ELISPOT assay provided direct
evidence that CD8+ T cells, purified from patients' blood
samples, are responsible for the production of IFN-γ. Autologous
or allogeneic HLA-matched APC can be used for ELISPOT assays
on purified CD4+ and CD8+ T cells. As the finite amount of blood
available from patients, autologous APC is rarely obtained in
sufficient numbers. Therefore, the use of a common allogeneic
peptide-presenting cell line appears advantageous. The human
mutant lymphoid cell line T2 was widely used as allo-APC for
HLA-A*0201-restricted CD8+ T cells. However, we and others
have observed that significant background spot formation
can be induce by T2-reactive T cells [39]. Under the high
‘background’, the mean +3SD of the negative control
triplicates was often selected as cutoff for positive
response base on receiver-operator characteristic analysis
for human or IFN-γ ELISPOT [23,40]. However, we observed
that a CD8+ T cell response targeting human IGRP peptide
IGRP265–273 was present in about 40% HLA-A*0201+ T1D
patients. IGRP265–273 peptide, which is completely conserved
between mouse and human IGRP, was originally identified in
HLA-A*0201 transgenic NOD mice [41] and subsequently
confirmed to be recognized by CD8+ T cells in some HLA-A2+
T1D patients [31]. Another study showed that 90% candidate
epitopes from GAD65 and insulinoma-associated protein
identified by immunization of HLA-A*0201 transgenic mice
were specifically recognized by CD8+ T cells from newly
diagnosed T1D patients with the different magnitude of
responses [23]. As the finite amount of blood available
from T1D patients, the HLA-A*0201-transgenic NOD mice
model is efficient to identify autoantigen-derived epi-
topes relevant to human T1D. Future studies will be
needed to more fully characterize the ChgA-specific CD8+
T cell responses in terms of human T1D pathogenesis.
In conclusion,we firstly found that ChgA-specific CD8+ T cells
were present in both HLA-A*0201 transgenic NOD mice and T1D
patients, and peptides ChgA10–19 and ChgA43–52 of murine and
human were identified as novel HLA-A*0201-restricted epitopes
that induce the proinflammatory and cytolytic response by CD8+
T cells. The identification of the ChgA peptides is an important
first step towards understanding their potential role in the
pathogenesis of T1D and their possible value in the future
research in human T1D patients.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.clim.2015.04.017.
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